SEATTLE, June 29, 2016 (GLOBE NEWSWIRE) -- Atlas Genomics, a privately held CLIA-certified high complexity molecular diagnostic laboratory located in Seattle, Washington, today announced an agreement with Henry Schein Medical, the U.S. Medical business of Henry Schein, Inc. (NASDAQ:HSIC), under which Henry Schein Medical will offer its customers Noninvasive Prenatal Testing (NIPT) and Carrier Screening by Atlas Genomics on an exclusive basis.
"We are absolutely thrilled to work with Henry Schein Medical as their laboratory for noninvasive prenatal testing and carrier screening,” said Dr. Michael Kalnoski, CEO and Medical Director of Atlas Genomics. “Henry Schein Medical’s national sales representatives provide direct access to the more than 25,000 OB/GYNs who currently conduct prenatal testing."
About Noninvasive Prenatal Testing
Noninvasive prenatal screening (NIPT), also called prenatal cell-free DNA (cfDNA) screening, is a method to screen for certain specific chromosomal abnormalities in a developing baby, including trisomy abnormalities.
During prenatal cell-free DNA screening, DNA from the mother and fetus is extracted from a maternal blood sample to screen for the increased chance for specific chromosome problems, such as Down syndrome.
About Atlas Genomics
Atlas Genomics is a CLIA-certified high complexity molecular diagnostic laboratory located in Seattle, Washington. The Company’s mission is to better the lives of patients by providing physicians with easy to-use access to the newest in molecular testing tools and to improve patient outcomes at reasonable cost. Atlas Genomics specializes in noninvasive prenatal testing, carrier screening, and other prenatal tests. The laboratory utilizes advanced technologies to deliver value to patients and physicians.
CONTACTS FOR ATLAS GENOMICS: Christopher S. Destro Vice President firstname.lastname@example.org (206) 310-2335 Matthew D. Haines (Media) Principal River East Investor Relations, LLC email@example.com (917) 733-9297
Source: Atlas Genomics